Khoso Baluch
Khoso Baluch's purchase track record
Khoso Baluch has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/31/2026 | PCSA | $6K | -24.0% | -30.3% | +17.5% |
| 12/28/2023 | LGVN | $14K | -76.6% | -87.9% | +14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Transaction History
| PCSA | ▲ Buy | Option Exercise | 203 | — | 6/26/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,269 | $6K | 3/31/2026 | View on chart |
| LGVN | ▲ Buy | Open Market | 11,766 | — | 8/11/2025 | View on chart |
| LGVN | ▲ Buy | Grant | 17,000 | $0 | 7/15/2025 | View on chart |
| LGVN | ▼ Sell | Open Market | 1,250 | $3K | 12/2/2024 | View on chart |
| LGVN | ▲ Buy | Grant | 23,500 | $0 | 8/15/2024 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 125 | $133 | 6/9/2024 | View on chart |
| LGVN | ▲ Buy | Open Market | 8,322 | $12K | 12/29/2023 | View on chart |
| LGVN | ▲ Buy | Open Market | 1,678 | $2K | 12/28/2023 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 15,455 | — | 6/27/2023 | View on chart |
| LGVN | ▲ Buy | Grant | 5,000 | $0 | 6/9/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 12,500 | $10K | 2/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.